Arrowhead’s Redemplo Wins UK Approval
Arrowhead Pharmaceuticals’ Redemplo received UK approval for a rare cholesterol disorder.
Related stories
India Regulator Recommends Ending Capital Gains Tax for Foreign Investors
India’s markets regulator has recommended that the government remove the long-term capital gains tax imposed on foreign investors, according to two people with direct knowledge of
L impact | REGULATION | Nov 02, 2026, 10:05 AM UTC
Singapore Orders Independent Review of Golden Agri Subsidiary
Singapore’s environment agency ordered an independent review of a Golden Agri subsidiary over transboundary air pollution.
L impact | REGULATION | Nov 02, 2026, 09:46 AM UTC
Gencurix Trading Halt Extended Pending Delisting Review Decision
Trading in Gencurix common shares on the KOSDAQ has been extended until a decision is made on whether grounds for delisting apply.
L impact | REGULATION | Nov 02, 2026, 09:34 AM UTC
Handal Energy Faces Bursa Delisting Over Overdue 2025 Annual Report
Handal Energy faces potential delisting from Bursa over its overdue 2025 annual report.
M impact | REGULATION | Nov 02, 2026, 09:25 AM UTC
Belgian Prime Minister Bart De Wever Submits Resignation to King
Reuters reports that Belgian Prime Minister Bart De Wever submitted his resignation to the king.
M impact | REGULATION | Nov 02, 2026, 09:23 AM UTC
FDA Approves Inovio Treatment; Shares More Than Triple Premarket
The FDA approved an Inovio treatment for a rare respiratory condition. Inovio shares more than tripled premarket.
M impact | REGULATION | Nov 02, 2026, 09:14 AM UTC